Abstract
We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10-21) weeks. The median overall survival was 70 (9-178) weeks and for responders it was 120 (22-178) weeks. One patient developed one episode of neutropenic sepsis. Docetaxel has limited activity in this group of patients.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Blood Cell Count
-
Disease-Free Survival
-
Docetaxel
-
Humans
-
Lymphoma, Non-Hodgkin / blood
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / mortality
-
Middle Aged
-
Paclitaxel / adverse effects
-
Paclitaxel / analogs & derivatives*
-
Paclitaxel / therapeutic use*
-
Prognosis
-
Survival Rate
-
Taxoids*
-
Time Factors
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Phytogenic
-
Taxoids
-
Docetaxel
-
Paclitaxel